Freyer, Gilles http://orcid.org/0000-0001-6001-164X
Floquet, Anne http://orcid.org/0000-0002-1078-8554
Tredan, Olivier
Carrot, Aurore
Langlois-Jacques, Carole
Lopez, Jonathan
Selle, Frédéric http://orcid.org/0000-0002-7016-5383
Abdeddaim, Cyril
Leary, Alexandra
Dubot-Poitelon, Coraline
Fabbro, Michel http://orcid.org/0000-0003-1910-4777
Gladieff, Laurence
Lamuraglia, Michele http://orcid.org/0000-0001-8009-0218
Funding for this research was provided by:
AstraZeneca (Not applicable)
Article History
Received: 29 December 2022
Accepted: 8 February 2024
First Online: 5 March 2024
Competing interests
: <b>GF</b>: honoraria (AstraZeneca, MSD, BMS, Lilly, GSK, Seagen, Daiichi-Sankyo); <b>AF</b>: honoraria (AstraZeneca, GSK, Clovis), meeting support (AstraZeneca, GSK, Pharma Mar), leadership in other board (GSK); <b>OT</b>: honoraria (Roche, Pfizer, Novartis-Sandoz, Lilly, MSD, AstraZeneca, Pierre Fabre, Seagen, Daiichi-Sankyo, Gilead, Eisai, Menarini-Stemline), meeting support (Roche, Pfizer, Novartis-Sandoz, Lilly, MSD, AstraZeneca, Seagen, Daiichi-Sankyo, Gilead), consulting/board (Roche, Pfizer, Novartis-Sandoz, Lilly, MSD, AstraZeneca, Pierre Fabre, Seagen, Daiichi-Sankyo, Gilead, Eisai); <b>FS</b>: consulting (AstraZeneca, MSD, GSK-Tesaro), honoraria (AstraZeneca, MSD, GSK-Tesaro), meeting support (AstraZeneca, MSD, GSK-Tesaro, Roche), <b>CA</b> grants (GSK), honoraria (GSK, Clovis Oncology, AstraZeneca), meeting support (GSK); <b>AL</b>: honoraria (AstraZeneca, GSK, Clovis), consulting (AstraZeneca, GSK, Clovis, MSD, Merck Serono, Ability, Zentalis),funded research (AstraZeneca, GSK, Clovis, MSD, Ability, Agenus, Iovance, Sanofi, Roche, OSEimmuno, BMS); <b>MF</b>: honoraria (AstraZeneca, GSK), consulting/board (AstraZeneca, GSK), <b>LG</b>: honoraria (AstraZeneca), meeting support (AstraZeneca). The remaining authors declare no competing interests (CL-J, CD, JL, AC, ML).